In a recent Form 13F filed with the U.S. Securities and Exchange Commission, Boston, Massachusetts-based institutional investment manager Arrowstreet Capital, L.P. disclosed that it substantially increased its stake in cannabinoid pharmaceutical innovator GW Pharmaceuticals Plc (NASDAQ:GWPH) during the most recent quarter.
Since then, GW Pharmaceuticals has reported strong fiscal Q1 financials as well as the completion of the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX. – this time for the treatment of seizures associated with Tuberous Sclerosis Complex.
With an estimated $98 billion in assets under management as of a recent Form ADV, Arrowstreet Capital, L.P.’s recent purchase of 11,895 additional shares of GW Pharma amounts to just a drop in the bucket for the firm. That being said, it is always a bullish signal that institutional investors and money managers like Arrowstreet Capital, L.P. are getting involved in cannabis investments.
Now, Arrowstreet Capital, L.P. holds 31,195 shares of GWPH, worth approximately $5,653,781.80 based on the last-traded price of $181.24 USD per share on the NASDAQ.
According to Bloomberg, “The firm primarily provides its services to pension and profit sharing plans. It also caters to pooled investment vehicles, investment companies, charitable organizations, corporations, state or municipal government entities, insurance companies, private foundations, endowments, and universities.”
We’ll continue to monitor 13F filings to see what institutional investors are up to. In the meantime, be sure to subscribe to updates here so you never miss an important update.
Get Real-Time Updates from MJobserver.com